CY1113159T1 - Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις - Google Patents

Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις

Info

Publication number
CY1113159T1
CY1113159T1 CY20121100902T CY121100902T CY1113159T1 CY 1113159 T1 CY1113159 T1 CY 1113159T1 CY 20121100902 T CY20121100902 T CY 20121100902T CY 121100902 T CY121100902 T CY 121100902T CY 1113159 T1 CY1113159 T1 CY 1113159T1
Authority
CY
Cyprus
Prior art keywords
competitives
glucagon
preparation
compounds
health uses
Prior art date
Application number
CY20121100902T
Other languages
Greek (el)
English (en)
Inventor
Scott Eugene Conner
Jianke Li
Guoxin Zhu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113159T1 publication Critical patent/CY1113159T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CY20121100902T 2005-11-17 2012-09-28 Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις CY1113159T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73762705P 2005-11-17 2005-11-17
EP06850109A EP1951661B1 (en) 2005-11-17 2006-11-07 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
CY1113159T1 true CY1113159T1 (el) 2016-04-13

Family

ID=38474434

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100902T CY1113159T1 (el) 2005-11-17 2012-09-28 Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις

Country Status (14)

Country Link
US (1) US7696248B2 (enExample)
EP (1) EP1951661B1 (enExample)
JP (1) JP5107253B2 (enExample)
CN (1) CN101309895B (enExample)
AU (1) AU2006340002B2 (enExample)
BR (1) BRPI0618349A2 (enExample)
CA (1) CA2629348C (enExample)
CY (1) CY1113159T1 (enExample)
DK (1) DK1951661T3 (enExample)
ES (1) ES2391109T3 (enExample)
PL (1) PL1951661T3 (enExample)
PT (1) PT1951661E (enExample)
SI (1) SI1951661T1 (enExample)
WO (1) WO2007106181A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1758853T3 (da) * 2004-06-14 2010-04-06 Lilly Co Eli Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
KR20170085615A (ko) 2007-02-09 2017-07-24 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR101616140B1 (ko) * 2008-03-05 2016-04-27 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
AR073412A1 (es) 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
PE20100443A1 (es) * 2009-02-06 2010-06-25 Takeda Pharmaceutical Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon
WO2011037815A1 (en) 2009-09-22 2011-03-31 Schering Corporation Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5694561B2 (ja) 2010-12-23 2015-04-01 ファイザー・インク グルカゴン受容体モジュレーター
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2014520093A (ja) * 2011-05-23 2014-08-21 ヤンセン ファーマシューティカ エヌ.ベー. グルカゴン受容体拮抗薬として有用なビフェニル誘導体
ES2557450T3 (es) * 2011-05-23 2016-01-26 Janssen Pharmaceutica, N.V. Derivados de ácido picolinamido-propanoico útiles como antagonistas de los receptores de glucagón
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013147026A1 (ja) * 2012-03-29 2013-10-03 武田薬品工業株式会社 芳香環化合物
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2016052300A (ja) * 2014-09-03 2016-04-14 日立化成株式会社 生体物質捕獲システム
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
WO2000069810A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
WO2004002480A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
AU2003291959A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
CA2600159A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
ES2391109T3 (es) 2012-11-21
EP1951661B1 (en) 2012-08-08
SI1951661T1 (sl) 2012-11-30
JP5107253B2 (ja) 2012-12-26
WO2007106181A2 (en) 2007-09-20
PL1951661T3 (pl) 2012-12-31
US7696248B2 (en) 2010-04-13
CN101309895A (zh) 2008-11-19
AU2006340002B2 (en) 2011-12-22
CN101309895B (zh) 2012-10-03
BRPI0618349A2 (pt) 2011-08-23
WO2007106181A3 (en) 2007-12-06
CA2629348A1 (en) 2007-09-20
CA2629348C (en) 2013-08-13
JP2009519226A (ja) 2009-05-14
US20080300308A1 (en) 2008-12-04
DK1951661T3 (da) 2012-09-03
PT1951661E (pt) 2012-09-19
AU2006340002A1 (en) 2007-09-20
EP1951661A2 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CY1118611T1 (el) Συνδυασμοι που περιεχουν παραγωγα της 6-βενζυλο-φαινυλο-2-θειοτετραϋδροπυραν-3,4,5-τριολης ως αναστολεις των συμμεταφορεων 1 και 2 νατριου-γλυκοζης για να χρησιμοποιηθουν σε διαβητικους ασθενεις
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
CY1112284T1 (el) Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
GT200500309A (es) Derivados de sulfonilbencilimidazol
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
NO20084677L (no) Anvendelse av kombinasjonspreparater som inneholder trombinreseptorantagonister for behandling av hjerte-karforstyrrelser
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
CY1113374T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις